IPAX-2
01 May 2023
Trial Summary
This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.
Acronym:
IPAX-2
ACTRN/NCT /ethics:
NCT05450744
Scientific title:
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Sponsor / Cooperative group:
Telix International Pty Ltd
Trial & Patient Characteristics
| Cancer Type | Brain |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2023-04-02 |
| Anticipated End Date | 2025-06-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| Anne.Milton@sa.gv.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Nimit Singhal |
| Recruitment Status | Recruiting |